Article

Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody

Biomedical Sciences Research Complex, University of St Andrews, St Andrews, Fife, KY16 9ST, UK.
Journal of Virology (Impact Factor: 4.44). 09/2012; 86(23). DOI: 10.1128/JVI.02052-12
Source: PubMed

ABSTRACT

The E2 envelope glycoprotein of HCV binds to the host entry factor CD81, and is the principal target for neutralizing antibodies (nAbs). Most nAbs recognize hypervariable region 1 on E2, which undergoes frequent mutation, thereby allowing the virus to evade neutralization. Consequently, there is great interest in nAbs that target conserved epitopes. One such nAb is AP33, a mouse monoclonal antibody that recognizes a conserved, linear epitope on E2 and potently neutralizes a broad range of HCV genotypes. In this study, the X-ray structure of AP33 Fab in complex with an epitope peptide spanning residues 412 to 423 of HCV E2 has been determined to 1.8Å. In the complex, the peptide adopts a β-hairpin conformation and docks into a deep binding pocket on the antibody. The major determinants of antibody recognition are E2 residues L413, N415, G418 and W420. The structure is compared to the recently described HCV1 Fab in complex with the same epitope. Interestingly, the antigen-binding sites of HCV1 and AP33 are completely different, whereas the peptide conformation is very similar in the two structures. Mutagenesis of the peptide-binding residues on AP33 confirmed that these residues are also critical for AP33 recognition of whole E2, confirming that the peptide-bound structure truly represents AP33 interaction with the intact glycoprotein. The slightly conformation-sensitive character of the AP33-E2 interaction was explored by cross-competition analysis and alanine-scanning mutagenesis. The structural details of this neutralizing epitope provide a starting point for the design of an immunogen capable of eliciting AP33-like antibodies.

Download full-text

Full-text

Available from: Arvind H Patel
  • Source
    • "In contrast, mAb 3/11 formed interactions with residues N415, W420, and H421 and neutralized the same panel of viruses with lower potency [35]. The interaction of AP33 with its epitope was subsequently confirmed by solving the crystal structure of the E2 peptide in complex with AP33 [67] [68]. Other mAbs recognizing this region have more recently been described, including human mAb HCV1 [39], which binds predominantly at positions L413 and W420 [69]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) is the major cause of chronic liver disease as well as the major indication for liver transplantation worldwide. Current standard of care is not completely effective, not administrable in grafted patients, and burdened by several side effects. This incomplete effectiveness is mainly due to the high propensity of the virus to continually mutate under the selective pressure exerted by the host immune response as well as currently administered antiviral drugs. The E2 envelope surface glycoprotein of HCV (HCV/E2) is the main target of the host humoral immune response and for this reason one of the major variable viral proteins. However, broadly cross-neutralizing monoclonal antibodies (mAbs) directed against HCV/E2 represent a promising tool for the study of virus-host interplay as well as for the development of effective prophylactic and therapeutic approaches. In the last few years many anti-HCV/E2 mAbs have been evaluated in preclinical and clinical trials as possible candidate antivirals, particularly for administration in pre- and post-transplant settings. In this review we summarize the antigenic and structural characteristics of HCV/E2 determined through the use of anti-HCV/E2 mAbs, which, given the absence of a crystal structure of this glycoprotein, represent currently the best tool available.
    Full-text · Article · Jul 2013 · Clinical and Developmental Immunology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Monoclonal antibodies (mAbs) have been used successfully both in research and for clinical purposes. The possible use of protective mAbs directed against different microbial pathogens is currently being considered. The fine definition of the epitope recognized by a protective mAb is an important aspect to be considered for possible development in epitope-based vaccinology. The most accurate approach to this is the X-ray resolution of mAb/antigen crystal complex. Unfortunately, this approach is not always feasible. Under this perspective, several surrogate epitope mapping strategies based on the use of bioinformatics have been developed. In this article, we review the most common, freely accessible, bioinformatic tools used for epitope characterization and provide some basic examples of molecular visualization, editing and computational analysis.
    Full-text · Article · Nov 2012 · Drug discovery today
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schutzimpfungen haben sich als wirksame präventive Maßnahme im Kampf gegen übertragbare Erkrankungen bewährt. Der vorliegende Artikel erläutert für die Hepatitis-A- und Hepatitis-B-Impfung die Indikationen, das Impfschema, die Ansprechraten, die Dauer des Impfschutzes sowie das Vorgehen bei speziellen Patientengruppen. Daten zur Effektivität der Impfung bei chronisch HCV-Koinfizierten werden ebenfalls bewertet. Ebenso wird auf Neuentwicklungen bei Hepatitis-C- sowie Hepatitis-E-Impfungen eingegangen. Abstract Vaccinations have shown to be an effective preventive strategy against transmitted diseases. The following article shows indications, vaccination scheme, response rates, duration of immune response and strategies for special groups of patients for hepatitis A and hepatitis B vaccination. Efficacy data regarding chronic hepatitis C virus (HCV) coinfected patients will be evaluated. In addition, new developments for hepatitis C and hepatitis E vaccination are discussed.
    No preview · Article · Jan 2013 · Der Gastroenterologe
Show more